|
1
|
Gharibvand L, Beeson WL, Shavlik D,
Knutsen R, Ghamsary M, Soret S and Knutsen SF: The association
between ambient fine particulate matter and incident adenocarcinoma
subtype of lung cancer. Environ Health. 16:712017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sartorius B and Sartorius K: How much
incident lung cancer was missed globally in 2012? An ecological
country-level study. Geospat Health. 11:3962016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bailey C, Hewison A, Karasouli E,
Staniszewska S and Munday D: Hospital care following emergency
admission: A critical incident case study of the experiences of
patients with advanced lung cancer and chronic obstructive
pulmonary disease. J Clin Nurs. 25:2168–2179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tual S, Silverman DT, Koutros S, Blair A,
Sandler DP, Lebailly P, Andreotti G, Hoppin JA and Freeman LE: Use
of dieselized farm equipment and incident lung cancer: Findings
from the Agricultural Health Study Cohort. Environ Health Perspect.
124:611–618. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Akamatsu H, Mori K, Naito T, Imai H, Ono
A, Shukuya T, Taira T, Kenmotsu H, Murakami H, Endo M, et al:
Progression-free survival at 2 years is a reliable surrogate marker
for the 5-year survival rate in patients with locally advanced
non-small cell lung cancer treated with chemoradiotherapy. BMC
Cancer. 14:182014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tian T, Wang J and Zhou X: A review:
MicroRNA detection methods. Org Biomol Chem. 13:2226–2238. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Silva BOD, Lima KF, Gonçalves LR, Silveira
MBD and Moraes KCM: Correction: MicroRNA profiling of the effect of
the heptapeptide angiotensin-(1–7) in A549 lung tumor cells reveals
a role for miRNA149-3p in cellular migration processes. PLoS One.
12:e01902042017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pastorkova Z, Skarda J and Andel J: The
role of microRNA in metastatic processes of non-small cell lung
carcinoma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.
160:343–357. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang HM, Kuang S, Xiong X, Gao T, Liu C
and Guo AY: Transcription factor and microRNA co-regulatory loops:
Important regulatory motifs in biological processes and diseases.
Brief Bioinform. 16:45–58. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kraemer A, Anastasov N, Angermeier M,
Winkler K, Atkinson MJ and Moertl S: MicroRNA-mediated processes
are essential for the cellular radiation response. Radiat Res.
176:575–586. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takamizawa J, Konishi H, Yanagisawa K,
Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y,
et al: Reduced expression of the let-7 microRNAs in human lung
cancers in association with shortened postoperative survival.
Cancer Res. 64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang DQ, Zhou CK, Jiang XW, Chen J and
Shi BK: Increased expression of miR-222 is associated with poor
prognosis in bladder cancer. World J Surg Oncol. 12:2412014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Köhler CU, Bryk O, Meier S, Lang K,
Rozynek P, Brüning T and Käfferlein HU: Analyses in human
urothelial cells identify methylation of miR-152, miR-200b and
miR-10a genes as candidate bladder cancer biomarkers. Biochem
Biophys Res Commun. 438:48–53. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Puerta-Gil P, García-Baquero R, Jia AY,
Ocaña S, Alvarez-Múgica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava
F and Sánchez-Carbayo M: miR-143, miR-222, and miR-452 are useful
as tumor stratification and noninvasive diagnostic biomarkers for
bladder cancer. Am J Pathol. 180:1808–1815. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deng H, Qianqian G, Ting J and Aimin Y:
miR-539 enhances chemosensitivity to cisplatin in non-small cell
lung cancer by targeting DCLK1. Biomed Pharmacother. 106:1072–1081.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Luo D, Zhang Z, Zhang Z, Li JY, Cui J, Shi
WP, Dong XW, Yuan L, Lin P, Chen ZN, et al: Aberrant expression of
miR-362 promotes lung cancer metastasis through downregulation of
Sema3A. J Immunol Res. 2018:16870972018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Y, Cui X, Li Y, Zhang T and Li S:
Upregulated expression of miR-421 is associated with poor prognosis
in non-small-cell lung cancer. Cancer Manag Res. 10:2627–2633.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jin S, He J, Li J, Guo R, Shu Y and Liu P:
MiR-873 inhibition enhances gefitinib resistance in non-small cell
lung cancer cells by targeting glioma-associated oncogene homolog
1. Thorac Cancer. 9:1262–1270. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng W, Zhao J, Tao Y, Guo M, Ya Z, Chen
C, Qin N, Zheng J, Luo J and Xu L: MicroRNA-21: A promising
biomarker for the prognosis and diagnosis of non-small cell lung
cancer. Oncol Lett. 16:2777–2782. 2018.PubMed/NCBI
|
|
21
|
Yu S, Geng S and Hu Y: miR-486-5p inhibits
cell proliferation and invasion through repressing GAB2 in
non-small cell lung cancer. Oncol Lett. 16:3525–3530.
2018.PubMed/NCBI
|
|
22
|
Yang TS, Yang XH, Wang XD, Wang YL, Zhou B
and Song ZS: MiR-214 regulate gastric cancer cell proliferation,
migration and invasion by targeting PTEN. Cancer Cell Int.
13:682013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wen Z, Lei Z, Jin-An M, Xue-Zhen L,
Xing-Nan Z and Xiu-Wen D: The inhibitory role of miR-214 in
cervical cancer cells through directly targeting mitochondrial
transcription factor A (TFAM). Eur J Gynaecol Oncol. 35:676–682.
2014.PubMed/NCBI
|
|
24
|
Cristóbal I, Caramés C, Madoz-Gúrpide J,
Rojo F, Aguilera O and García-Foncillas J: Downregulation of
miR-214 is specific of liver metastasis in colorectal cancer and
could play a role determining the metastatic niche. Int J
Colorectal Dis. 29:8852014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Long H, Wang Z, Chen J, Xiang T, Li Q,
Diao X and Zhu B: microRNA-214 promotes epithelial-mesenchymal
transition and metastasis in lung adenocarcinoma by targeting the
suppressor-of-fused protein (Sufu). Oncotarget. 6:38705–38718.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liao J, Lin J, Lin D, Zou C, Kurata J, Lin
R, He Z and Su Y: Down-regulation of miR-214 reverses erlotinib
resistance in non-small-cell lung cancer through up-regulating LHX6
expression. Sci Rep. 7:7812017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu H, Tao Y, Chen M, Yu J, Li WJ, Tao L,
Li Y and Li F: Upregulation of microRNA-214 contributes to the
development of vascular remodeling in hypoxia-induced pulmonary
hypertension via targeting CCNL2. Sci Rep. 6:246612016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shenoy SK, Han S, Zhao YL, Hara MR, Oliver
T, Cao Y and Dewhirst MW: β-arrestin1 mediates metastatic growth of
breast cancer cells by facilitating HIF-1-dependent VEGF
expression. Oncogene. 31:282–292. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Y, Zhao Q, Ma S, Yang F, Gong Y and
Ke C: Sirolimus inhibits human pancreatic carcinoma cell
proliferation by a mechanism linked to the targeting of mTOR/HIF-1
alpha/VEGF signaling. IUBMB Life. 59:717–721. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015. View Article : Google Scholar
|
|
32
|
Grelet S, Link LA, Howley B, Obellianne C,
Palanisamy V, Gangaraju VK, Diehl JA and Howe PH: A regulated PNUTS
mRNA to lncRNA splice switch mediates EMT and tumour progression.
Nat Cell Biol. 19:1105–1115. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen Y, Huang Y, Hou P, Zhang Z, Zhang Y,
Wang W, Sun G, Xu L, Zhou J, Bai J and Zheng J: ING4 suppresses
tumor angiogenesis and functions as a prognostic marker in human
colorectal cancer. Oncotarget. 7:79017–79031. 2016.PubMed/NCBI
|
|
34
|
Wang CJ, Yang D and Luo YW: Recombinant
ING4 suppresses the migration of SW579 thyroid cancer cells via
epithelial to mesenchymal transition. Exp Ther Med. 10:603–607.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang QS, Li M, Zhang LY, Jin Y, Tong DD,
Yu Y, Bai J, Huang Q, Liu FL, Liu A, et al: Down-regulation of ING4
is associated with initiation and progression of lung cancer.
Histopathology. 57:271–281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Peng R, Men J, Ma R, Wang Q, Wang Y, Sun Y
and Ren J: miR-214 down-regulates ARL2 and suppresses growth and
invasion of cervical cancer cells. Biochem Biophys Res Commun.
484:623–630. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu J, Li D, Dang L, Liang C, Guo B, Lu C,
He X, Cheung HY, He B, Liu B, et al: Osteoclastic miR-214 targets
TRAF3 to contribute to osteolytic bone metastasis of breast cancer.
Sci Rep. 7:404872017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J,
Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA and Cheng
JQ: MicroRNA miR-214 regulates ovarian cancer cell stemness by
targeting p53/Nanog. J Biol Chem. 291:228512016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang C, Ding M, Xia M, Chen S, Van Le A,
Soto-Gil R, Shen Y, Wang N, Wang J, Gu W, et al: A five-miRNA panel
identified from a multicentric case-control study serves as a novel
diagnostic tool for ethnically diverse non-small-cell lung cancer
patients. EBioMedicine. 2:1377–1385. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ding G, Huang G, Liu HD, Liang HX, Ni YF,
Ding ZH, Ni GY and Hua HW: MiR-199a suppresses the hypoxia-induced
proliferation of non-small cell lung cancer cells through targeting
HIF1α. Mol Cell Biochem. 384:173–180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu Y, Bernauer AM, Yingling CM and
Belinsky SA: HIF1α regulated expression of XPA contributes to
cisplatin resistance in lung cancer. Carcinogenesis. 33:1187–1192.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Eleftheriadis SG, Sivridis E, Koutsopoulos
A, Galatoudis ZG, Chloropoulou PA, Koukourakis MI, Didilis VN,
Bougioukas GI and Giatromanolaki A: One-lung ventilation and
HIF1alpha expression in lung cancer and pneumothorax. Anticancer
Res. 30:1143–1148. 2010.PubMed/NCBI
|
|
44
|
Carbajo-Pescador S, Ordoñez R, Benet M,
Jover R, García-Palomo A, Mauriz JL and González-Gallego J:
Inhibition of VEGF expression through blockade of Hif1α and STAT3
signalling mediates the anti-angiogenic effect of melatonin in
HepG2 liver cancer cells. Br J Cancer. 109:83–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kafousi M, Vrekoussis T, Tsentelierou E,
Pavlakis K, Navrozoglou I, Dousias V, Sanidas E, Tsiftsis D,
Georgoulias V and Stathopoulos EN: Immunohistochemical study of the
angiogenetic network of VEGF, HIF1α, VEGFR-2 and endothelial nitric
oxide synthase (eNOS) in human breast cancer. Pathol Oncol Res.
18:33–41. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Giatromanolaki A, Koukourakis MI, Turley
H, Sivridis E, Harris AL and Gatter KC; Tumour; Angiogenesis
Research Group, : Phosphorylated KDR expression in endometrial
cancer cells relates to HIF1alpha/VEGF pathway and unfavourable
prognosis. Mod Pathol. 19:701–707. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
O'Rourke JF, Pugh CW, Bartlett SM and
Ratcliffe PJ: Identification of hypoxically inducible mRNAs in HeLa
cells using differential-display PCR. Role of hypoxia-inducible
factor-1. Eur J Biochem. 241:403–410. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nobumoto M, Yamada M, Song S, Inouye S and
Nakazawa A: Mechanism of mitochondrial import of adenylate kinase
isozymes. J Biochem. 123:128–135. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chang X, Ravi R, Pham V, Bedi A,
Chatterjee A and Sidransky D: Adenylate kinase 3 sensitizes cells
to cigarette smoke condensate vapor induced cisplatin resistance.
PLoS One. 6:e208062011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li M, Zhu Y, Zhang H, Li L, He P, Xia H,
Zhang Y and Mao C: Delivery of inhibitor of growth 4 (ING4) gene
significantly inhibits proliferation and invasion and promotes
apoptosis of human osteosarcoma cells. Sci Rep. 4:73802014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li S, Fan T, Liu H, Chen J, Qin C and Ren
X: Tumor suppressor ING4 overexpression contributes to
proliferation and invasion inhibition in gastric carcinoma by
suppressing the NF-κB signaling pathway. Mol Biol Rep.
40:5723–5732. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Colla S, Tagliaferri S, Morandi F, Lunghi
P, Donofrio G, Martorana D, Mancini C, Lazzaretti M, Mazzera L,
Ravanetti L, et al: The new tumor-suppressor gene inhibitor of
growth family member 4 (ING4) regulates the production of
proangiogenic molecules by myeloma cells and suppresses
hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: Involvement
in myeloma-induced angiogenesis. Blood. 110:4464–4475. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ozer A, Wu LC and Bruick RK: The candidate
tumor suppressor ING4 represses activation of the hypoxia inducible
factor (HIF). Proc Natl Acad Sci USA. 102:7481–7486. 2005.
View Article : Google Scholar : PubMed/NCBI
|
